A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer

C. Casey Cunningham, Jon T. Holmlund, Joan H. Schiller, Richard S. Geary, T. Jesse Kwoh, Andrew Dorr, John Nemunaitis

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic transformation and tumor cell proliferation. ISIS 5132 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically down-regulates c-raf expression. We report here an initial study of the safety and tolerability of an i.v. infusion of ISIS 5132 in patients with advanced cancer. A continuous i.v. infusion of ISIS 5132 was administered for 21 days every 4 weeks to 34 patients with a variety of solid tumors refractory to standard therapy. The dose of ISIS 5132 was increased in sequential cohorts of patients, as toxicity allowed, until a final dose of 5.0 mg/kg body weight was reached. Toxicity was scored by common toxicity criteria, and tumor response was monitored. Pharmacokinetic studies were performed for 30 patients treated at doses of ≤4.0 mg/kg/day. The initial dose of ISIS 5132 was 0.5 mg/kg body weight and was successfully increased incrementally to 5.0 mg/kg body weight. Toxicities through the 4.0 mg/kg dose level were not dose limiting. Side effects were minimal and could not be specifically related to ISIS 5132. Two patients had prolonged stabilization of their disease, and one patient with ovarian carcinoma had a significant response with a 97% reduction in CA-125 levels. ISIS 5132, an antisense oligonucleotide against c-raf, was well tolerated at doses up to and including 4.0 mg/kg/day by 21-day continuous i.v. infusion and demonstrated antitumor activity at the doses tested.

Original languageEnglish (US)
Pages (from-to)1626-1631
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number5
StatePublished - May 2000

Fingerprint

Proto-Oncogene Proteins c-raf
Antisense Oligonucleotides
Intravenous Infusions
Neoplasms
Body Weight
Antisense Oligodeoxyribonucleotides
ISIS 5132
Mitogen-Activated Protein Kinases
Down-Regulation
Pharmacokinetics
Cell Proliferation
Carcinoma
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cunningham, C. C., Holmlund, J. T., Schiller, J. H., Geary, R. S., Kwoh, T. J., Dorr, A., & Nemunaitis, J. (2000). A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clinical Cancer Research, 6(5), 1626-1631.

A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. / Cunningham, C. Casey; Holmlund, Jon T.; Schiller, Joan H.; Geary, Richard S.; Kwoh, T. Jesse; Dorr, Andrew; Nemunaitis, John.

In: Clinical Cancer Research, Vol. 6, No. 5, 05.2000, p. 1626-1631.

Research output: Contribution to journalArticle

Cunningham, CC, Holmlund, JT, Schiller, JH, Geary, RS, Kwoh, TJ, Dorr, A & Nemunaitis, J 2000, 'A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer', Clinical Cancer Research, vol. 6, no. 5, pp. 1626-1631.
Cunningham, C. Casey ; Holmlund, Jon T. ; Schiller, Joan H. ; Geary, Richard S. ; Kwoh, T. Jesse ; Dorr, Andrew ; Nemunaitis, John. / A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 5. pp. 1626-1631.
@article{3f5ebb3189304d23b66acc9dcde3e4e7,
title = "A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer",
abstract = "Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic transformation and tumor cell proliferation. ISIS 5132 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically down-regulates c-raf expression. We report here an initial study of the safety and tolerability of an i.v. infusion of ISIS 5132 in patients with advanced cancer. A continuous i.v. infusion of ISIS 5132 was administered for 21 days every 4 weeks to 34 patients with a variety of solid tumors refractory to standard therapy. The dose of ISIS 5132 was increased in sequential cohorts of patients, as toxicity allowed, until a final dose of 5.0 mg/kg body weight was reached. Toxicity was scored by common toxicity criteria, and tumor response was monitored. Pharmacokinetic studies were performed for 30 patients treated at doses of ≤4.0 mg/kg/day. The initial dose of ISIS 5132 was 0.5 mg/kg body weight and was successfully increased incrementally to 5.0 mg/kg body weight. Toxicities through the 4.0 mg/kg dose level were not dose limiting. Side effects were minimal and could not be specifically related to ISIS 5132. Two patients had prolonged stabilization of their disease, and one patient with ovarian carcinoma had a significant response with a 97{\%} reduction in CA-125 levels. ISIS 5132, an antisense oligonucleotide against c-raf, was well tolerated at doses up to and including 4.0 mg/kg/day by 21-day continuous i.v. infusion and demonstrated antitumor activity at the doses tested.",
author = "Cunningham, {C. Casey} and Holmlund, {Jon T.} and Schiller, {Joan H.} and Geary, {Richard S.} and Kwoh, {T. Jesse} and Andrew Dorr and John Nemunaitis",
year = "2000",
month = "5",
language = "English (US)",
volume = "6",
pages = "1626--1631",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer

AU - Cunningham, C. Casey

AU - Holmlund, Jon T.

AU - Schiller, Joan H.

AU - Geary, Richard S.

AU - Kwoh, T. Jesse

AU - Dorr, Andrew

AU - Nemunaitis, John

PY - 2000/5

Y1 - 2000/5

N2 - Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic transformation and tumor cell proliferation. ISIS 5132 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically down-regulates c-raf expression. We report here an initial study of the safety and tolerability of an i.v. infusion of ISIS 5132 in patients with advanced cancer. A continuous i.v. infusion of ISIS 5132 was administered for 21 days every 4 weeks to 34 patients with a variety of solid tumors refractory to standard therapy. The dose of ISIS 5132 was increased in sequential cohorts of patients, as toxicity allowed, until a final dose of 5.0 mg/kg body weight was reached. Toxicity was scored by common toxicity criteria, and tumor response was monitored. Pharmacokinetic studies were performed for 30 patients treated at doses of ≤4.0 mg/kg/day. The initial dose of ISIS 5132 was 0.5 mg/kg body weight and was successfully increased incrementally to 5.0 mg/kg body weight. Toxicities through the 4.0 mg/kg dose level were not dose limiting. Side effects were minimal and could not be specifically related to ISIS 5132. Two patients had prolonged stabilization of their disease, and one patient with ovarian carcinoma had a significant response with a 97% reduction in CA-125 levels. ISIS 5132, an antisense oligonucleotide against c-raf, was well tolerated at doses up to and including 4.0 mg/kg/day by 21-day continuous i.v. infusion and demonstrated antitumor activity at the doses tested.

AB - Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic transformation and tumor cell proliferation. ISIS 5132 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically down-regulates c-raf expression. We report here an initial study of the safety and tolerability of an i.v. infusion of ISIS 5132 in patients with advanced cancer. A continuous i.v. infusion of ISIS 5132 was administered for 21 days every 4 weeks to 34 patients with a variety of solid tumors refractory to standard therapy. The dose of ISIS 5132 was increased in sequential cohorts of patients, as toxicity allowed, until a final dose of 5.0 mg/kg body weight was reached. Toxicity was scored by common toxicity criteria, and tumor response was monitored. Pharmacokinetic studies were performed for 30 patients treated at doses of ≤4.0 mg/kg/day. The initial dose of ISIS 5132 was 0.5 mg/kg body weight and was successfully increased incrementally to 5.0 mg/kg body weight. Toxicities through the 4.0 mg/kg dose level were not dose limiting. Side effects were minimal and could not be specifically related to ISIS 5132. Two patients had prolonged stabilization of their disease, and one patient with ovarian carcinoma had a significant response with a 97% reduction in CA-125 levels. ISIS 5132, an antisense oligonucleotide against c-raf, was well tolerated at doses up to and including 4.0 mg/kg/day by 21-day continuous i.v. infusion and demonstrated antitumor activity at the doses tested.

UR - http://www.scopus.com/inward/record.url?scp=0034026007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034026007&partnerID=8YFLogxK

M3 - Article

C2 - 10815879

AN - SCOPUS:0034026007

VL - 6

SP - 1626

EP - 1631

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -